Key result
OAGB drives greater excess weight loss and lower BMI versus RYGB and SG with similar complications.
Why the study?
The efficacy and safety of one anastomosis gastric bypass compared to Roux-en-Y gastric bypass and sleeve gastrectomy in the surgical treatment of obesity remain ill-defined.
Does one anastomosis gastric bypass improve weight loss and metabolic outcomes compared to Roux-en-Y gastric bypass or sleeve gastrectomy in patients with obesity?
Meta-Analysis (n=854)
Does one anastomosis gastric bypass improve weight loss and metabolic outcomes compared to Roux-en-Y gastric bypass or sleeve gastrectomy in patients with obesity?
One anastomosis gastric bypass offers comparable or slightly superior weight loss efficacy to traditional bariatric procedures without increasing complications, though the overall quality of evidence remains very low.
OAGB may offer superior weight loss with comparable safety; leaves open confirmation in high-quality RCTs given very low evidence.
BACKGROUND: One anastomosis gastric bypass (OAGB) has gained prominence in the search for better results in bariatric surgery. However, its efficacy and safety compared to Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) remain ill-defined. AIMS: To compare the efficacy and safety of OAGB relative to RYGB and SG in the treatment of obesity. METHODS: We systematically searched PubMed, EMBASE, Cochrane Library, Lilacs, and Google Scholar databases for randomized controlled trials comparing OAGB with RYGB or SG in the surgical approach to obesity. We pooled outcomes for body mass index, percentage of excess weight loss, type-2 diabetes mellitus remission, complications, and gastroesophageal reflux disease. Statistical analyses were performed with R software (version 4.2.3). RESULTS: Data on 854 patients were extracted from 11 randomized controlled trials, of which 422 (49.4%) were submitted to OAGB with mean follow-up ranging from six months to five years. The meta-analysis revealed a significantly higher percentage of excess weight loss at 1-year follow-up and a significantly lower body mass index at 5-year follow-up in OAGB patients. Conversely, rates of type-2 diabetes mellitus remission, complications, and gastroesophageal reflux disease were not significantly different between groups. The overall quality of evidence was considered very low. CONCLUSIONS: Our results corroborate the comparable efficacy of OAGB in relation to RYGB and SG in the treatment of obesity, maintaining no significant differences in type-2 diabetes mellitus remission, complications, and gastroesophageal reflux disease rates.
No takes yet. Share an insight, caveat, or question.
Onzi et al. (2024) conducted a meta-analysis in Obesity (n=854). One anastomosis gastric bypass (OAGB) vs. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) was evaluated on Body mass index, percentage of excess weight loss, type-2 diabetes mellitus remission, complications, and gastroesophageal reflux disease. One anastomosis gastric bypass resulted in significantly higher excess weight loss at 1 year and lower body mass index at 5 years compared to RYGB and SG, with similar complication rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: